Mid-Week Stocks To Watch Include Tesla, Palantir, and More
After enjoying a nearly uninterrupted rally since April, Tesla (TSLA) and Palantir (PLTR) are showing signs of sell-off risks.CEO Elon Musk harshly criticized Trump’s Big, Beautiful Bill. Although the billionaire should have expected the GOP to support oil and gas markets and cut subsidies for electric vehicles, Musk might incite change.The CEO called for the U.S. to form a new political party.Palantir peaked at $148.22 last week but closed at $130.68. The firm hired Accenture’s (ACN) federal services unit as its preferred implementation partner. Palantir continues to win deals with federal agencies. It will need the consultant’s help in training and certifying customers on Palantir Foundry and the Artificial Intelligence Platform.In the AI space, BigBear.ai (BBAI) shares are still trending higher. It gained 68.78% in the last month. On June 17, the firm said it deployed multiple biometric software systems to process passengers at airports.In the industrials sector, beware of Plug Power’s (PLUG) recent rally. Shares traded below $1.00 throughout May. However, after the Senate bill unexpectedly included clean hydrogen tax credit extensions, PLTR stock traded as high as $1.50. Investors should instead consider Air Products (APD), Linde (LIN), and Bloom Energy (BE). Peabody Energy (BTU) and Canadian Natural Resources (CNR) are also attractive alternatives.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


